Human respiratory syncytial virus and coronavirus rates in Iranian elderly patients more than 60 years old with acute respiratory symptoms
Shaian Tavakolian1, Hossein Goudarzi1, Ilad Alavi Darazam2, Ebrahim Faghihloo1
1 Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran 2 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Date of Submission | 19-Nov-2022 |
Date of Acceptance | 31-Jan-2023 |
Date of Web Publication | 20-Jul-2023 |
Correspondence Address: Dr. Ebrahim Faghihloo Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/abr.abr_395_22
Background: Scientists have believed that a number of risk factors, especially viral infectious agents, can be related to respiratory diseases. Due to the pandemics in 2019, Human Respiratory Syncytial Virus and Coronavirus have attracted the attention of different kinds of research. In this study, we attempted to evaluate the prevalence of these viruses. Materials and Methods: After extracting the RNA and DNA of these viruses, molecular tests were employed to report the rate of them in patients suffering from respiratory symptoms. Results: Our results demonstrated that 31 samples were COVID-19 positive. Furthermore, two cases had Respiratory syncytial virus (RSV) subgroup A infections. However, no cases showed a coinfection of both viruses. Conclusions: It seems that during the pandemic of COVID-19, RSV should not be ignored as it can be responsible for the respiratory syndrome.
Keywords: Coronavirus, epidemiology, RSV
How to cite this article: Tavakolian S, Goudarzi H, Alavi Darazam I, Faghihloo E. Human respiratory syncytial virus and coronavirus rates in Iranian elderly patients more than 60 years old with acute respiratory symptoms. Adv Biomed Res 2023;12:180 |
How to cite this URL: Tavakolian S, Goudarzi H, Alavi Darazam I, Faghihloo E. Human respiratory syncytial virus and coronavirus rates in Iranian elderly patients more than 60 years old with acute respiratory symptoms. Adv Biomed Res [serial online] 2023 [cited 2023 Sep 28];12:180. Available from: https://www.advbiores.net/text.asp?2023/12/1/180/382071 |
Introduction | |  |
Despite a progression in the health-care system, most scientists believe that respiratory diseases can cause high rates of mortality. This health problem is the third cause of death in developed countries, especially in European countries, comprising 440 000 in 2015.[1],[2] In the current age, greenhouse gasses, such as carbon dioxide emitted from numerous transportation systems, can progress this disease detrimentally. Unfortunately, some other risk factors can have the same effects on the public, ranging from smoking to tobacco smoking (including second-hand smoke) to allergens.[3]
However, infectious agents are other items that have been in the center of concentration. Take, for example, Respiratory syncytial virus (RSV) infection, which can account for one of the infant mortality (less than 1 year of age worldwide).[4] This virus belongs to the genus Orthopneumovirus, family Pneumoviridae, and order Mononegavirales.[5],[6],[7],[8] In terms of structure, this virus has an envelope and spherical capsid, packaging a negative-sense RNA genome.[9] A meta-analysis illustrated that approximately 160 000 kids (less than 5 years of age) died in 2015 due to this virus.[10] RSV usually leads to pneumonia and bronchiolitis when they are newborns[11]; nevertheless, elders need to be hospitalized in cold seasons because of this virus.[12] Two subgroups of RSV can be observed, including subgroups A and B, which can react with monoclonal antibodies directed against the G protein.[13]
Another virus that is suffering patients is the Coronavirus, and some health problems can be related to this virus, including severe acute respiratory syndrome (SARS), the common cold, and the Middle East respiratory syndrome (MERS).[14] This virus, which was less known before 2019, cast a shadow all around the world as it caused a pandemic called COVID-19. Around 620 000 and 27 000 individuals were infected and passed away, respectively, until April 15, 2020 in the United States.[15] Saliva, droplets, or discharges from the nose of an infected individual after coughing or sneezing can spread COVID-19. These viruses belong to Coronaviridae, and scientists classified them into four distinct genera, including Alpha coronavirus, Beta coronavirus, Delta coronavirus, and Gamma coronavirus. Nevertheless, only alpha and beta coronaviruses are able to infect mammals.[16] There is a spike (S) protein composed of more than 1300 amino acids that is responsible for interacting with cell receptors. Indeed, they can recognize zinc peptidase angiotensin-converting enzyme 2 (ACE2), and some other receptors.[17],[18] They usually enter the cells through endocytosis, and lysosomal proteases process their spike. Single-strand RNA accounts for virus reproduction since it uses the ribosome of the host cell to replicate polyproteins.[19] It should be mentioned that the non-structural genes of COVID-19 are located within the 5′-proximal two-thirds of the genome on gene 1; however, the 3′-proximal one-third of the genome (8–9 genes for coronaviruses) encodes the structural proteins.[20]
As both RSV and Coronavirus can spread quickly, causing high rates of death all around the world such as COVID-19, we attempted to evaluate the prevalence of these viruses in 2021, when there was a pandemic of Coronavirus.
Materials and Methods | |  |
Samples
The ethical code of this article, which is approved by Shahid Beheshti University of Medical Sciences, is” IR.SBMU.MSP.REC.1399.164 (Grant no 23305). In this case-control study, we collected 79 samples of people in Loghman Hospital, Tehran, Iran, who had some symptoms, such as wheezing, coughing, and fever, between January and September 2021. All patients were more than 60 years old, and written consent was given from all of them for publications of this article. These throat swab specimens were obtained from patients with influenza-like illness and maintained in a viral transport medium. These swabs with ice packs were transported and stored at the Shahid Beheshti University of Medical Sciences. After collection, all samples were stored in =80°C in the Shahid Beheshti University of Medical Sciences Microbiology Department.
RNA extraction and cDNA synthesis for respiratory syncytial virus
RNA from throat swabs was extracted by the RSV RNA Extraction Kit (ViraGen, India), and we dissolved it in 50 ul of elution buffer. After that, 17.5 μL of extracted RNA was combined with 2.5 μL of dNTP, 1 μL of RT enzyme of moloney murine leukemia virus, 6 μL of RT buffer, 2.5 of μL random hexamer primers, and 0.5 μL of RNase inhibitor in a total volume of 30 μL. This mixture was incubated at 37°C for 45 min, according to the kit.
Primer sequences for respiratory syncytial virus
In the external step, forward primers were applied with GPB (nt 494-515, 5'-AAGATGATTACCATTTTGAAGT-3') and GPA (nt 511-530, 5'- GAAGTGTTCAACTTTGTACC-3') for subgroup B and subgroup A, respectively. We performed hemi-nested PCR step using nRSAG (nt 539-558, 5'- TATGCAGCAACAATCCAACC-3') as HRSV-A specific forward primer, and Nrsbg (nt 512-531, 5'-GTGGCAACAATCAACTCTGC-3') as HRSV-B specific forward primer. Common reverse primers for subgroups A and B called F1 (nt 3-22, 5'-CAACTCCATTGTTATTTGCC-3') in both external and hemi-nested polymerase chain reaction steps were employed.
External PCR for respiratory syncytial virus
27 ul of distilled water, 5 ul of 10X PCR buffer, 2 ul of dNTP, 2 ul of Mgcl2, 1 ul of Taq DNA polymerase, 1.5 ul of reverse primer, 1.5 ul of forward primer, and 10 ul of synthesized cDNA were mixed to perform PCR in the external step. The PCR schedule was 5 min at 94°C, which was followed by 35 cycles of 94°C for 30 sec, 50°C for 30 sec, 72°C for 30 sec, and finally 72°C for 10 min. The final product for external PCR was 450 bp in gel electrophoresis.
Hemi-nested PCR for respiratory syncytial virus
Hemi-nested PCR steps had a similar pattern to the external ones, yet with a 400-bp final product. We used the standard HRSV A2 strain as a positive control; moreover, negative control was utilized to confirm our clinical performances. We run our final products in 1.5% agarose gel electrophoresis under Ultraviolet light.
Real-time PCR test to detect SARS-COV2 RNA
We employed a one-Step RT-PCR COVID-19 kit from Pishtaz Teb Company. Two viral genes (namely RNA-dependent RNA polymerase (RdRp) and (N) Nucleocapsid) were targeted by this kit containing a primer and probe for the RNase P gene to prevent false negatives in the extraction steps. After amplification, we evaluated the internal control in the channel, ROX, and negative and positive controls in the FAM and HEX channels. The negative and positive controls had no fluorescence signal and a Ct ≤35 cycles, respectively. The positive threshold of this kit for both genes and the internal control should be Ct ≤40 with the sigmoid S curve.
Results | |  |
We examined 79 samples (42 male and 37 female) of elders, including 23, 27, and 29 individuals who were in sixth, seventh, and eighth of their lives, suffering from respiratory diseases. Our results demonstrated that 31 samples were COVID-19 positive. Furthermore, two cases had RSV subgroup A infections, but no cases showed a coinfection of both viruses [Table 1] and [Table 2].
Discussion | |  |
Unfortunately, health problems in some parts of the body, such as the sinuses, throat, airways, or lungs, can be responsible for the growing trend of death in the world.[21] Being a host to different kinds of infectious agents, which can occur because of exposure to animals, is likely to be a reason why some epidemics can be observed since a number of studies have reported this issue.[22],[23] Given the fact that these viruses are able to spread as easily as possible, evaluating their prevalence can give a new perspective to solve this problem. In terms of geography, we should compare a number of regions to understand the effects of vaccines, social distance, or other ways of virus transmission. In this study, we reported the incidence of two significant viruses in a Middle East country called Iran, which experienced fluctuations in Coronavirus death rates during the COVID-19 pandemic. The limitation of this study is the low number of samples, as it is difficult to collect them from the hospitals.
We found that among 79 patients suffering from respiratory diseases, two samples were RSV subgroup A infections positive. Some researchers have published the epidemiology of this infectious agent. For instance, a meta-analysis conducted on Iranian samples illustrated that 775 (18.7%) out of 4140 patients had RSV infections from 1996 to 2013.[24] Around 67% and 33% of 297 specimens from South Korean infants or children between 2008 and 2009 had HRSV-A and HRSV-B, respectively.[25] In Brazil, most RSV-positive people's mean age was lower than the negative ones, and researchers found this virus in 243 (23.1%) children. In this study, RSV was detected, with a predominance in Group B (209/227), and 10% of them suffered from bacterial infections.[26] Mathur and colleagues in a serologic study found that 32 patients had RSV, while 24 individuals had Influenza among 71 cases, and they reported that RSV can be significant in elders.[27] In 2018, 45.3% and 53.7% were subtypes A and B, respectively, and only 1% of hospitalized persons had both of these viruses. Moreover, they believe that the more age increases, the more chance of RSV-B infections can be observed.[28]
Another virus assessed in this study was the Coronavirus, and 31 samples were COVID-19 positive. In 2020, Desai and colleagues conducted a study to evaluate the outbreak of this virus. They found that 13.2% of patients with a mean age >50, but younger patients (mean age <50 years) illustrated a pooled prevalence of 9.0%.[29] A review in the USA showed that COVID-19 can take a heavy toll on elders, such as the highest mortality rates, hospitalizations, and hospitalizations in the intensive care unit.[30] During the COVID-19 pandemic, researchers suggested that some risk factors ranging from inherent immunity, temperature-humidity variation, to lower life expectancy can effect on the Coronavirus prevalence, which is the reason why in numerous countries we are likely to observe different rates of this virus.[31] It seems that this virus has a higher rate among cardiovascular and metabolic diseases in comparison with intensive care unit severe and non-ICU/severe patients.[32] Another study reported that patients with diabetes who suffered from COVID-19 had more severe symptoms.[33] More than 60% of patients hospitalized due to SARS-CoV-2 had post-COVID-19 symptoms.[34]
Conclusion | |  |
It seems that during the pandemic of COVID-19, RSV should not be ignored as it can be responsible for the respiratory syndrome.
Financial support and sponsorship
The ethical code of this article, which is approved by Shahid Beheshti University of Medical Sciences, is” IR.SBMU.MSP.REC.1399.164 (Grant no 23305).
Conflicts of interest
There are no conflicts of interest.
References | |  |
1. | Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: A literature review. Thorax 2013;68:1057-65. |
2. | Matta S, Chopra KK, Arora VK. Morbidity and mortality trends of Covid 19 in top 10 countries. Indian J Tuberc 2020;67:S167-72. |
3. | Walker SL, Saltman DL, Colucci R, Martin L. Canadian Lung Association Advisory Committee. Awareness of risk factors among persons at risk for lung cancer, chronic obstructive pulmonary disease and sleep apnea: A Canadian population-based study. Can Respir J 2010;17:287-94. |
4. | Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: A modelling study. Lancet 2018;391:1285-300. |
5. | Niazadeh M, Nikkhahi F, Robatjazi S, Javadi A, Farzam SA, Babaei S, et al. Evaluation of mechanisms of colistin resistance in Klebsiella pneumoniae strains isolated from patients with urinary tract infection in ICU. Iran J Microbiol 2022; 14:31-37. |
6. | Davoudabadi S, Goudarzi H, Goudarzi M, Ardebili A, Faghihloo E, et al. Detection of extensively drug-resistant and hypervirulent Klebsiella pneumoniae ST15, ST147, ST377 and ST442 in Iran. Acta Microbiol Immunol Hung 2021. |
7. | Haghroosta A, Goudarzi H, Ghalavand Z, Faghihloo E, Pilehchian Langroudi R. Molecular cloning of a new bi-functional fusion protein of clostridium perfringens type A alpha and clostridium septicum alpha toxin genes in E. coli. Arch Clin Infect Dis 2020;15:e95502. |
8. | Haghroosta A, Goudarzi H, Faghihloo E, Ghalavand Z, Ranjbar MM, Langroudi RP. In silico analysis of a chimeric fusion protein as a new vaccine candidate against clostridium perfringens type A and clostridium septicum alpha toxins. Comp Clin Path 2020;29:981-9. |
9. | McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Sci 2013; 340:1113-7. |
10. | Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 2010;375:1545-55. |
11. | Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 2022;386:837-46. |
12. | Ye RZ, Que TC, Xia LY, Cui XM, Zhang YW, Jiang JF, et al. Natural infection of pangolins with human respiratory syncytial viruses. Curr Biol 2022;32:R307-8. |
13. | Bergeron HC, Tripp RA. RSV replication, transmission, and disease are influenced by the RSV G protein. Viruses 2022;14:2396. |
14. | Amanat F, Krammer F. SARS-CoV-2 vaccines: Status report. Immunity 2020;52:583-9. |
15. | Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. |
16. | Perlman S, Netland J. Coronaviruses post-SARS: Update on replication and pathogenesis. Nat Rev Microbiol 2009;7:439-50. |
17. | Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;26:450-4. |
18. | Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pöhlmann S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A 2005;102:7988-93. |
19. | Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-80.e8. |
20. | Brian DA, Baric RS. Coronavirus genome structure and replication. Curr Top Microbiol Immunol 2005;287:1-30. |
21. | Sato M, Saito R, Sakai T, Sano Y, Nishikawa M, Sasaki A, et al. Molecular epidemiology of respiratory syncytial virus infections among children with acute respiratory symptoms in a community over three seasons. J Clin Microbiol 2005;43:36-40. |
22. | Temmam S, Vongphayloth K, Baquero E, Munier S, Bonomi M, Regnault B, et al. Bat coronaviruses related to SARS-CoV-2 and infectious for human cells. Nature 2022;604:330-6. |
23. | Intisar KS, Ali YH, Khalafalla AI, Rahman ME, Amin AS. Respiratory syncytial virus infection of camels (Camelus dromedaries). Acta Trop 2010;113:129-33. |
24. | Salimi V, Tavakoli-Yaraki M, Yavarian J, Bont L, Mokhtari-Azad T. Prevalence of human respiratory syncytial virus circulating in Iran. J Infect Public Health 2016;9:125-35. |
25. | Baek YH, Choi EH, Song MS, Pascua PN, Kwon HI, Park SJ, et al. Prevalence and genetic characterization of respiratory syncytial virus (RSV) in hospitalized children in Korea. Arch Virol 2012;157:1039-50. |
26. | Lamarão LM, Ramos FL, Mello WA, Santos MC, Barbagelata LS, Justino MC, et al. Prevalence and clinical features of respiratory syncytial virus in children hospitalized for community-acquired pneumonia in northern Brazil. BMC Infect Dis 2012;12:119. |
27. | Mathur U, Bentley DW, Hall CB. Concurrent respiratory syncytial virus and influenza A infections in the institutionalized elderly and chronically ill. Ann Intern Med 1980;93:49-52. |
28. | Ruzin A, Pastula ST, Levin-Sparenberg E, Jiang X, Fryzek J, Tovchigrechko A, et al. Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States. PLoS One 2018;13:e0200319. |
29. | Desai R, Singh S, Parekh T, Sachdeva S, Sachdeva R, Kumar G. COVID-19 and diabetes mellitus: A need for prudence in elderly patients from a pooled analysis. Diabetes Metab Syndr 2020;14:683-5. |
30. | Shahid Z, Kalayanamitra R, McClafferty B, Kepko D, Ramgobin D, Patel R, et al. COVID-19 and older adults: What we know. J Am Geriatr Soc 2020;68:926-9. |
31. | Khalil I, Barma P. Sub-continental atmosphere and inherent immune system may have impact on novel corona virus' 2019 (nCovid-19) prevalence in South East Asia. Mymensingh Med J 2020;29:473-80. |
32. | Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020;109:531-8. |
33. | Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr 2020;14:303-10. |
34. | Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Florencio LL, Cuadrado ML, Plaza-Manzano G, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. Eur J Intern Med 2021;92:55-70. |
[Table 1], [Table 2]
|